EZB8RISK / Market Verdict

RNAi sector buzz lifts ALNY

Alnylam is rallying moderately alongside a risk-on biotech tape, with news that a startup co-founded by its founder filed for IPO drawing fresh attention to the RNAi field the company pioneered.

Sources: https://www.bizjournals.com/boston/news/2026/09/25/john-maraganore-s-new-rnai-startup-plots-ipo.html

Sources

[1]

Ezbrisk weighs each event against the market reaction and publishes a verdict with an overreaction reading. How the methodology works

Open the live Ezbrisk dashboard Browse the archive